SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Enveric Biosciences, Inc. – ‘S-4/A’ on 8/12/20 – ‘ZIP’

On:  Wednesday, 8/12/20, at 5:14pm ET   ·   Accession #:  1493152-20-15374   ·   File #:  333-238742

Previous ‘S-4’:  ‘S-4’ on 5/28/20   ·   Next:  ‘S-4/A’ on 9/17/20   ·   Latest:  ‘S-4/A’ on 8/4/21   ·   25 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/12/20  AMERI Holdings, Inc.              S-4/A                113:17M                                    M2 Compliance LLC/FA

Pre-Effective Amendment to Registration Statement – Securities for a Merger   —   Form S-4   —   SA’33
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-4/A       Pre-Effective Amendment to Registration Statement   HTML   5.25M 
                - Securities for a Merger                                        
 2: EX-23.4     Consent of Expert or Counsel                        HTML     29K 
 3: EX-23.5     Consent of Expert or Counsel                        HTML     29K 
 4: EX-99.2     Miscellaneous Exhibit                               HTML     30K 
 5: EX-99.3     Miscellaneous Exhibit                               HTML     31K 
 6: EX-99.4     Miscellaneous Exhibit                               HTML     31K 
 7: EX-99.5     Miscellaneous Exhibit                               HTML     31K 
 8: EX-99.6     Miscellaneous Exhibit                               HTML     31K 
 9: EX-99.7     Miscellaneous Exhibit                               HTML     31K 
16: R1          Document and Entity Information                     HTML     43K 
17: R2          Condensed Consolidated Balance Sheets               HTML    137K 
18: R3          Condensed Consolidated Balance Sheets               HTML     47K 
                (Parenthetical)                                                  
19: R4          Condensed Consolidated Statements of Operations     HTML    144K 
                and Comprehensive Income (Loss)                                  
20: R5          Consolidated Statement of Changes in Stockholders'  HTML    116K 
                Equity                                                           
21: R6          Condensed Consolidated Statements of Cash Flows     HTML    113K 
22: R7          Description of Business                             HTML     39K 
23: R8          Summary of Significant Accounting Policies          HTML     93K 
24: R9          Basis of Presentation                               HTML     36K 
25: R10         Equity Transactions                                 HTML     50K 
26: R11         Business Combinations                               HTML     89K 
27: R12         Revenue Recognition                                 HTML     41K 
28: R13         Intangible Assets                                   HTML     45K 
29: R14         Goodwill                                            HTML     37K 
30: R15         Share-Based Compensation                            HTML     34K 
31: R16         Equity Compensation Plans                           HTML     67K 
32: R17         Warrants Outstanding                                HTML     46K 
33: R18         Earnings (Loss) Per Share                           HTML     54K 
34: R19         Incentive Plan Items                                HTML     31K 
35: R20         Bank Debt                                           HTML     34K 
36: R21         Debt                                                HTML     42K 
37: R22         Accrued Expenses and Other Current Liabilities      HTML     35K 
38: R23         Employee Benefit Plan                               HTML     31K 
39: R24         Income Taxes                                        HTML     44K 
40: R25         Leases                                              HTML     46K 
41: R26         Convertible Notes                                   HTML     34K 
42: R27         Commitments and Contingencies                       HTML     48K 
43: R28         Fair Value Measurement                              HTML     53K 
44: R29         Revision of Prior Year Financial Statements         HTML    102K 
45: R30         Preferred Stock                                     HTML     32K 
46: R31         Secured Note                                        HTML     32K 
47: R32         Subsequent Events                                   HTML     63K 
48: R33         Summary of Significant Accounting Policies          HTML    147K 
                (Policies)                                                       
49: R34         Summary of Significant Accounting Policies          HTML     37K 
                (Tables)                                                         
50: R35         Business Combinations (Tables)                      HTML     62K 
51: R36         Earnings (Loss) Per Share (Tables)                  HTML     49K 
52: R37         Commitments and Contingencies (Tables)              HTML     60K 
53: R38         Warrants Outstanding (Tables)                       HTML     48K 
54: R39         Intangible Assets (Tables)                          HTML     45K 
55: R40         Goodwill (Tables)                                   HTML     35K 
56: R41         Equity Compensation Plans (Tables)                  HTML     66K 
57: R42         Debt (Tables)                                       HTML     35K 
58: R43         Accrued Expenses and Other Current Liabilities      HTML     34K 
                (Tables)                                                         
59: R44         Income Taxes (Tables)                               HTML     38K 
60: R45         Leases (Tables)                                     HTML     60K 
61: R46         Fair Value Measurement (Tables)                     HTML     47K 
62: R47         Revision of Prior Year Financial Statements         HTML     99K 
                (Tables)                                                         
63: R48         Description of Business (Details Narrative)         HTML     31K 
64: R49         Description of Business (Details Narrative) (10-K)  HTML     55K 
65: R50         Summary of Significant Accounting Policies          HTML     43K 
                (Details Narrative) (10-K)                                       
66: R51         Summary of Significant Accounting Policies -        HTML     48K 
                Schedule of Disaggregation of Revenue (Details)                  
67: R52         Equity Transactions (Details Narrative) (10-K)      HTML    117K 
68: R53         Business Combinations (Details Narrative)           HTML     69K 
69: R54         Business Combinations (Details Narrative) (10-K)    HTML    115K 
70: R55         Business Combinations - Summary of Foregoing        HTML     83K 
                Acquisitions (Details)                                           
71: R56         Intangible Assets (Details Narrative)               HTML     32K 
72: R57         Intangible Assets (Details Narrative) (10-K)        HTML     37K 
73: R58         Intangible Assets - Schedule of Components of       HTML     39K 
                Intangible Assets (Details) (10-K)                               
74: R59         Intangible Assets - Schedule of Future              HTML     38K 
                Amortization of Intangible Assets (Details) (10-K)               
75: R60         Goodwill (Details Narrative)                        HTML     32K 
76: R61         Goodwill (Details Narrative) (10-K)                 HTML     32K 
77: R62         Goodwill - Schedule of Goodwill (Details) (10-K)    HTML     35K 
78: R63         Share-Based Compensation (Details Narrative)        HTML     37K 
                (10-K)                                                           
79: R64         Equity Compensation Plans (Details Narrative)       HTML     38K 
                (10-K)                                                           
80: R65         Equity Compensation Plans - Schedule of Option      HTML     72K 
                Activity (Details) (10-K)                                        
81: R66         Earnings (Loss) Per Share - Schedule of Earnings    HTML     65K 
                Per Share Basic and Diluted (Details)                            
82: R67         Incentive Plan Items (Details Narrative)            HTML     31K 
83: R68         Bank Debt (Details Narrative)                       HTML     45K 
84: R69         Debt (Details Narrative) (10-K)                     HTML     75K 
85: R70         Debt - Schedule of Short Term Debt (10-K)           HTML     37K 
                (Details)                                                        
86: R71         Accrued Expenses and Other Current Liabilities -    HTML     44K 
                Schedule of Accrued Expenses and Other Liabilities               
                (Details) (10-K)                                                 
87: R72         Employee Benefit Plan (Details Narrative) (10-K)    HTML     36K 
88: R73         Income Taxes (Details Narrative) (10-K)             HTML     36K 
89: R74         Income Taxes - Schedule of Provision for Income     HTML     52K 
                Tax (10-K) (Details)                                             
90: R75         Convertible Notes (Details Narrative)               HTML     53K 
91: R76         Commitments and Contingencies (Details Narrative)   HTML     39K 
92: R77         Commitments and Contingencies - Schedule of         HTML     35K 
                Components of Lease Expense (Details)                            
93: R78         Commitments and Contingencies - Schedule of         HTML     38K 
                Supplemental Balance Sheet Information Related to                
                Leases (Details)                                                 
94: R79         Commitments and Contingencies - Schedule of         HTML     39K 
                Supplemental Cash Flow and Other Information                     
                Related to Leases (Details)                                      
95: R80         Commitments and Contingencies - Schedule of         HTML     49K 
                Maturity Payments of Operating Leases (Details)                  
96: R81         Warrants Outstanding - Schedule of Warrant          HTML     45K 
                Outstanding (Details)                                            
97: R82         Warrants Outstanding - Schedule of Warrants         HTML     52K 
                Activity (Details) (10-K)                                        
98: R83         Preferred Stock (Details Narrative)                 HTML     39K 
99: R84         Secured Note (Details Narrative)                    HTML     35K 
100: R85         Leases (Details Narrative) (10-K)                   HTML     34K  
101: R86         Leases - Schedule of Components of Lease Expense    HTML     35K  
                (Details) (10-K)                                                 
102: R87         Leases - Schedule of Supplemental Balance Sheet     HTML     38K  
                Information Related to Leases (Details) (10-K)                   
103: R88         Leases - Schedule of Supplemental Cash Flow and     HTML     39K  
                Other Information Related to Leases (Details)                    
                (10-K)                                                           
104: R89         Leases - Schedule of Maturity Payments of           HTML     44K  
                Operating Leases (Details) (10-K)                                
105: R90         Fair Value Measurement - Schedule of Financial      HTML     40K  
                Assets Measured at Fair Value (10-K) (Details)                   
106: R91         Fair Value Measurement - Schedule of Fair Value     HTML     39K  
                Change in Levels (10-K) (Details)                                
107: R92         Revision of Prior Year Financial Statements -       HTML    133K  
                Schedule of Consolidated Financial Statements                    
                Previously (Details)                                             
108: R93         Revision of Prior Year Financial Statements -       HTML    138K  
                Schedule of Consolidated Financial Statements                    
                Previously (Details) (10-K)                                      
109: R94         Subsequent Events (Details Narrative)               HTML     55K  
110: R95         Leases - Schedule of Supplemental Cash Flow and     HTML     39K  
                Other Information Related to Leases (Details)                    
112: XML         IDEA XML File -- Filing Summary                      XML    205K  
111: EXCEL       IDEA Workbook of Financial Reports                  XLSX    151K  
10: EX-101.INS  XBRL Instance -- amrh-20200331                       XML   2.20M 
12: EX-101.CAL  XBRL Calculations -- amrh-20200331_cal               XML    211K 
13: EX-101.DEF  XBRL Definitions -- amrh-20200331_def                XML    644K 
14: EX-101.LAB  XBRL Labels -- amrh-20200331_lab                     XML   1.16M 
15: EX-101.PRE  XBRL Presentations -- amrh-20200331_pre              XML    993K 
11: EX-101.SCH  XBRL Schema -- amrh-20200331                         XSD    235K 
113: ZIP         XBRL Zipped Folder -- 0001493152-20-015374-xbrl      Zip    203K  


‘ZIP’   —   XBRL Zipped Folder — 0001493152-20-015374-xbrl


This is an XBRL Zipped Folder.

        Download this zipped .zip folder
 
Files:amrh-20200331.xml
amrh-20200331.xsd
amrh-20200331_cal.xml
amrh-20200331_def.xml
amrh-20200331_lab.xml
amrh-20200331_pre.xml


5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/06/21  Enveric Biosciences, Inc.         8-K:1,2,3,512/30/20   13:1M                                     M2 Compliance LLC/FA
11/10/20  Enveric Biosciences, Inc.         S-4/A                121:18M                                    M2 Compliance LLC/FA
11/09/20  Enveric Biosciences, Inc.         S-4/A                122:18M                                    M2 Compliance LLC/FA
10/22/20  Enveric Biosciences, Inc.         S-4/A                123:18M                                    M2 Compliance LLC/FA
 9/17/20  Enveric Biosciences, Inc.         S-4/A       9/16/20  118:18M                                    M2 Compliance LLC/FA


20 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/28/20  Enveric Biosciences, Inc.         S-4         5/27/20   98:16M                                    M2 Compliance LLC/FA
 5/06/20  Enveric Biosciences, Inc.         8-K:1,2,3,9 5/06/20    6:372K                                   Broadridge Fin’l So… Inc
 3/04/20  Enveric Biosciences, Inc.         8-K:1,2,9   2/27/20    3:91K                                    Broadridge Fin’l So… Inc
 1/13/20  Enveric Biosciences, Inc.         8-K:1,3,8,9 1/10/20    9:2M                                     Broadridge Fin’l So… Inc
11/25/19  Enveric Biosciences, Inc.         8-K:1,2,9  11/25/19    3:297K                                   Broadridge Fin’l So… Inc
 8/14/19  Enveric Biosciences, Inc.         S-3                    5:1.1M                                   Broadridge Fin’l So… Inc
 3/26/19  Enveric Biosciences, Inc.         10-K       12/31/18   73:7.1M                                   Broadridge Fin’l So… Inc
 1/25/19  Enveric Biosciences, Inc.         8-K:1,2,9   1/23/19    6:465K                                   Broadridge Fin’l So… Inc
12/14/18  Enveric Biosciences, Inc.         8-K:3,5,9  12/10/18    3:97K                                    Broadridge Fin’l So… Inc
10/17/18  Enveric Biosciences, Inc.         8-K:1,5,9  10/16/18    3:78K                                    Olshan Frome Wolosky LLP
 8/17/18  Enveric Biosciences, Inc.         8-K:1,3,5,8 8/16/18    5:254K                                   Olshan Frome Wolosky LLP
 7/30/18  Enveric Biosciences, Inc.         8-K:1,3,8,9 7/25/18    6:613K                                   Olshan Frome Wolosky LLP
 6/26/18  Enveric Biosciences, Inc.         8-K:1,9     6/22/18    3:282K                                   Olshan Frome Wolosky LLP
 3/02/18  Enveric Biosciences, Inc.         8-K:1,9     2/28/18    2:37K                                    Olshan Frome Wolosky LLP
 3/08/17  Enveric Biosciences, Inc.         8-K:1,3,9   3/02/17    4:169K                                   Olshan Frome Wolosky LLP
 1/04/17  Enveric Biosciences, Inc.         8-K:1,3,5,912/30/16    3:146K                                   Olshan Frome Wolosky LLP
 6/23/16  Enveric Biosciences, Inc.         8-K:5,9     6/21/16    3:254K                                   Olshan Frome Wolosky LLP
12/17/15  Enveric Biosciences, Inc.         S-8        12/17/15    4:480K                                   Olshan Frome Wolosky LLP
11/23/15  Enveric Biosciences, Inc.         10-Q        9/30/15   32:1.3M                                   Edgar.Tech Fili… Svcs/FA
 6/01/15  Enveric Biosciences, Inc.         8-K:1,2,3,4 5/26/15   15:1.9M                                   Olshan Frome Wolosky LLP
Top
Filing Submission 0001493152-20-015374   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 15, 9:22:07.2pm ET